In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biodesix/Aveo: A Harbinger Of Deals To Come

Executive Summary

Aveo Pharmaceuticals and Biodesix have entered into a worldwide agreement to develop and commercialize Aveo’s ficlatuzumab, an antibody that inhibits hepatocyte growth factor, using Biodesix’s serum-based companion diagnostic VeriStrat, which guides treatment decisions for patients with advanced non-small cell lung cancer.

Advertisement

Related Content

When Illumina Buys Roche: The Dawning Of The Era Of Diagnostics Dominance

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel